Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
British Journal of Clinical Pharmacology|December 1, 2015
Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptinHimanshu Naik, Richard Czerniak, Majid Vakilynejad
Drugs in R&D|March 1, 2018
Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic ImpairmentJohn Marcinak, Majid Vakilynejad, Akifumi Kogame, et al.
Journal of Clinical Pharmacology|December 4, 2015
Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 HypertensionMax C Tsai, Jingtao Wu, Stuart Kupfer, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 17, 2018
Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modelingYeshitila Gebremichael, Gezim Lahu, Majid Vakilynejad, et al.
Clinical and Translational Science|March 6, 2024
Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathiesWei Yin, Axel Facius, Mahnaz Asgharnejad, et al.
Frontiers in Physiology|June 19, 2023
A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotidesAndreas A Linninger, Dipak Barua, Yaming Hang, et al.
Plos One|July 11, 2013
A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on DialysisHimanshu Naik, Max C Tsai, Jill Fiedler-Kelly, et al.
Clinical and Translational Science|May 22, 2023
Population pharmacokinetics, enzyme occupancy, and 24S-hydroxycholesterol modeling of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in healthy adultsWei Yin, Axel Facius, Thomas Wagner, et al.
Journal of Clinical Pharmacology|May 26, 2011
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteersHimanshu Naik, Majid Vakilynejad, Jingtao Wu, et al.
Basic & Clinical Pharmacology & Toxicology|November 4, 2015
A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive DisorderHimanshu Naik, Serena Chan, Majid Vakilynejad, et al.
Pageof 3